

Data Inspeksi Cara Uji Klinik Yang Baik (CUKB)

No	Judul Protokol	Sponsor	ORK	Sentra Uji Klinik	Peneliti	Jenis Produk Uji	Nama Produk Uji	Tanggal Mulai Pelaksanaan	Tanggal Selesai Pelaksanaan	Status CAPA	Tindakan Regulator
1	Immunogenicity And Safety Following In-house Recombinant Hepatitis B (bio Farma) Vaccine Compared To Hepatitis B (bio Farma)® Vaccine In Indonesian Population	PT BIO FARMA		Departemen Ilmu Kesehatan Anak Fakultas Kedokteran Universitas Udayana, RSUP Prof. Dr. I.G.N.G Ngoerah, Bali a. Puskesmas 1 Denpasar Selatan	Dr. dr. I Gusti Ayu Trisna Windiani, SpA(K)	Vaksin	Hepatitis B Vaccine	01-12-2025	03-12-2025	Dalam Proses Pemenuhan	NA
2	A Phase I Randomized, Double-blind, Placebo- Controlled And Dose-escalation Study To Evaluate The Safety And Immunogenicity Of A Viral Vector-based Tuberculosis (tb) Vaccine Ad5-105k Against Tb Disease In Adults Aged 18 To 49 Years	PT. Etana Biotechnologies Indonesia	PT. Increase Laboratorium Indonesia	Rumah Sakit Islam Jakarta (RSIJ) Cempaka Putih	DR. dr. Erlina Burhan, Sp.P(K), MSc dr. Fanny Fachrucha, Sp.P(K)	Vaksin	Ad5-105K	06-10-2025	07-10-2025	Closed	NA
3	A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Clinical Trial To Assess The Prophylactic Efficacy, Safety, And Immunogenicity Of The Investigational M72/as01e-4 Mycobacterium Tuberculosis (mtb) Vaccine When Administered Intramuscularly On A 0,1-month Schedule To Adolescents And Adults	Gates Medical Research Institute	PT IQVIA RDS Indonesia	RS Universitas Indonesia	DR. dr. Erlina Burhan, Sp.P(K), MSc dr. Rania Imaniar, Sp.P	Vaksin	M72/AS01E-4	11-08-2025	12-08-2025	Closed	NA
4	A Phase I/ii Randomized, Double-blind, Positive-controlled Dose-exploration Study To Evaluate The Safety And Immunogenicity Of A Virus-like Particle (vlp) Based Vaccine Against Poliomyelitis (vlp-polio) In Infants From 6 Weeks Of Age And Toddlers 12-18 Months Of Age	CanSino Biologics Inc.	Tigermed Consulting Indonesia	RSUP Prof. Dr. I.G.N.G Ngoerah, Denpasar	dr. Nina Dwi Putri, Sp.A SubslPT (K), MSc Dr. dr. I Made Gede Dwi Lingga Utama, Sp.A (K)	Vaksin	VLP-Polio	07-08-2025	08-08-2025	Closed	NA
5	A Randomized, Double-blind, Multicenter, Phase I/iii Clinical Study Of Serplulimab In Combination With Bevacizumab And Chemotherapy (xelox) Versus Placebo In Combination With Bevacizumab And Chemotherapy (xelox) In First-line Treatment Of Patients With Metastatic Colorectal Cancer (mcrC)	Shanghai Henlius Biotech, Inc.	PT. Pharma Metric Labs	RSU Sentra Medika Cibinong	Dr. dr. Andika Rachman Sp.PD-KHOM	Obat	Serplulimab	21-07-2025	22-07-2025	Dalam Proses Pemenuhan	NA
6	A Phase Iii, Randomized, Investigator-blinded, Active Controlled Study Of Efficacy And Safety Of Efepoetin Alfa For Treatment Of Anemia In Patients With Chronic Kidney Disease On Dialysis	Genexine, Inc.	PT. Pharma Metric Labs	Rumah Sakit Islam Jakarta, Cempaka Putih	dr. Pringgodigdo Nugroho, Sp.PD-KGH dr. Kuspuji Dwitanto Rahardjo, Sp.PD-KGH	Produk Biologi	Efepoetin Alfa	17-07-2025	18-07-2025	Closed	NA
7	A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Clinical Trial To Assess The Prophylactic Efficacy, Safety, And Immunogenicity Of The Investigational M72/as01e-4 Mycobacterium Tuberculosis (mtb) Vaccine When Administered Intramuscularly On A 0,1-month Schedule To Adolescents And Adults	Gates Medical Research Institute	PT IQVIA RDS Indonesia	RSUP Persahabatan	Dr. dr. Erlina Burhan, Sp.P(K), MSc Dr. dr. Fathiyah Isbaniah, M.Pd.Ked., Sp.P(K)	Vaksin	M72/AS01E-4	07-05-2025	08-05-2025	Closed	NA
8	A Multi-center, Randomized, Blinded, Active-controlled, Phase 3 Clinical Study To Evaluate The Immunogenicity And Safety Of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine Co-administered With Hexavalent Vaccine At 2, 4 And 12-15 Months Of Age To Health Infants In Indonesia	Minhai Biotechnology Co., Ltd	PT. Prodia DiaCRO Laboratories	Program Studi Magister Ilmu Kesehatan Masyarakat Fakultas Kedokteran Universitas Udayana	Dr. dr. I Gusti Ayu Trisna Windiani, SpA(K)	Vaksin	PCV13-TT	06-05-2025	08-05-2025	Closed	NA
9	A Phase I/ii Randomized, Double-blind, Positive-controlled Dose-exploration Study To Evaluate The Safety And Immunogenicity Of A Virus-like Particle (vlp) Based Vaccine Against Poliomyelitis (vlp-polio) In Infants From 6 Weeks Of Age And Toddlers 12-18 Months Of Age	CanSino Biologics Inc.	Tigermed Consulting, Co., Ltd. Indonesia	RSUPN Dr. Cipto Mangunkusumo	dr. Nina Dwi Putri, Sp.A SubslPT (K), MSc	Vaksin	VLP-Polio	29-04-2025	30-04-2025	Closed	NA
10	A Multi-center, Randomized, Blinded, Active-controlled, Phase 3 Clinical Study To Evaluate The Immunogenicity And Safety Of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine Co-administered With Hexavalent Vaccine At 2, 4 And 12-15 Months Of Age To Health Infants In Indonesia	Minhai Biotechnology Co., Ltd	PT Prodia Diacro Laboratories	Departemen Ilmu Kesehatan Anak FK Universitas Padjadjaran/ RSUP dr. Hasan Sadikin Bandung a. Puskesmas Ibrahim Adjie b. Puskesmas Garuda	Dr. dr. Eddy Fadlyana, Sp.A(K), MKes.	Vaksin	Pneuminvac	21-04-2025	22-04-2025	Closed	NA
11	A Randomized, Double-blind, Multicenter, Phase I/iii Clinical Study Of Serplulimab In Combination With Bevacizumab And Chemotherapy (xelox) Versus Placebo In Combination With Bevacizumab And Chemotherapy (xelox) In First-line Treatment Of Patients With Metastatic Colorectal Cancer (mcrC)	1. Shanghai Henlius Biotech, Inc. 2. PT Kalbe Genexine Biologics	PT. Pharma Metric Labs	RS MRCCC Siloam Semanggi	Prof. Dr. dr. Aru Wisaksono Sudoyo, SpPD-KHOM, FACP dr. Ralph Girson Gunarsa Sp.PD-KHOM	Obat	Serplulimab	19-03-2025	20-03-2025	Closed	NA
12	A Phase Iii, Randomized, Investigator-blinded, Active Controlled Study Of Efficacy And Safety Of Efepoetin Alfa For Treatment Of Anemia In Patients With Chronic Kidney Disease On Dialysis	Genexine, Inc.	PT. Pharma Metric Labs	Rumah Sakit Pusat Angkatan Darat Gatot Soebroto	dr. Jonny, Sp.PD-KGH, M.Kes., MM	Produk Biologi	Efepoetin Alfa	17-03-2025	18-03-2025	Closed	NA
13	A Phase I/ii Randomized, Double-blind, Positive-controlled Dose-exploration Study To Evaluate The Safety And Immunogenicity Of A Virus-like Particle (vlp) Based Vaccine Against Poliomyelitis (vlp-polio) In Infants From 6 Weeks Of Age And Toddlers 12-18 Months Of Age	CanSino Biologics Inc.	Tigermed Consulting Indonesia	RS Universitas Airlangga	Prof. Dr. dr. Nasronudin, Sp.PD., KPTI-FINASIM	Vaksin	VLP-Polio	26-02-2025	27-02-2025	Closed	NA
14	A Phase I/ii Randomized, Double-blind, Positive-controlled Dose-exploration Study To Evaluate The Safety And Immunogenicity Of A Virus-like Particle (vlp) Based Vaccine Against Poliomyelitis (vlp-polio) In Infants From 6 Weeks Of Age And Toddlers 12-18 Months Of Age	CanSino Biologics Inc.	Tigermed Consulting Indonesia	RSUP Prof. Dr. I.G.N.G Ngoerah, Denpasar	Dr. dr. I Made Gede Dwi Lingga Utama, Sp.A (K)	Vaksin	VLP-Polio	23-01-2025	24-01-2025	Closed	NA
15	A Phase I/ii Randomized, Double-blind, Positive-controlled Dose-exploration Study To Evaluate The Safety And Immunogenicity Of A Virus-like Particle (vlp) Based Vaccine Against Poliomyelitis (vlp-polio) In Infants From 6 Weeks Of Age And Toddlers 12-18 Months Of Age	PT Etana Biotechnologies Indonesia	Tigermed Consulting, Co., Ltd. Indonesia	RSUPN Dr. Cipto Mangunkusumo	dr. Nina Dwi Putri, Sp.A.SubslPT(K), MSc dr. Nina Dwi Putri, Sp.A.SubslPT(K), MSc	Vaksin	VLP-Polio	09-12-2024	10-12-2024	Closed	NA
16	A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Clinical Trial To Assess The Prophylactic Efficacy, Safety, And Immunogenicity Of The Investigational M72/as01e-4 Mycobacterium Tuberculosis (mtb) Vaccine When Administered Intramuscularly On A 0,1-month Schedule To Adolescents And Adults	Bill & Melinda Gates Medical Research Institute	PT IQVIA RDS Indonesia	Rumah Sakit Islam Jakarta Cempaka Putih	Prof. Dr. dr. Erlina Burhan, Sp.P(K), MSc dr. Cut Yulia Indah Sari, Sp.P	Vaksin	M72/AS01E-4	02-12-2024	03-12-2024	Closed	NA

No	Judul Protokol	Sponsor	ORK	Sentra Uji Klinik	Peneliti	Jenis Produk Uji	Nama Produk Uji	Tanggal Mulai Pelaksanaan	Tanggal Selesai Pelaksanaan	Status CAPA	Tindakan Regulator
17	A Phase I/ii Randomized, Double-blind, Positive-controlled Dose-exploration Study To Evaluate The Safety And Immunogenicity Of A Virus-like Particle (vlp) Based Vaccine Against Poliomyelitis (vlp-polio) In Infants From 6 Weeks Of Age And Toddlers 12-18 Months Of Age	PT Etana Biotechnologies Indonesia	Tigermed Consulting, Co., Ltd. Indonesia	RS Universitas Airlangga	dr. Nina Dwi Putri, SpA.SubstIPT(K), MSc Prof. Dr. Nasronudin dr., Sp.PD., KPTI.FINASIM	Vaksin	VLP-Polio	02-12-2024	03-12-2024	Closed	NA
18	A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Clinical Trial To Assess The Prophylactic Efficacy, Safety, And Immunogenicity Of The Investigational M72/as01e-4 Mycobacterium Tuberculosis (mtb) Vaccine When Administered Intramuscularly On A 0,1-month Schedule To Adolescents And Adults	Bill & Melinda Gates Medical Research Institute	PT IQVIA RDS Indonesia	Fakultas Kedokteran Universitas Indonesia a. Puskesmas Kramat Jati b. Puskesmas Kemayoran	Prof. Dr. dr. Erlina Burhan, Sp.P(K), MSc Prof. Dr. dr. Sri Rezeki Hadinegoro, Sp.A(K)	Vaksin	M72/AS01E-4	28-11-2024	29-11-2024	Closed	NA
19	A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Clinical Trial To Assess The Prophylactic Efficacy, Safety, And Immunogenicity Of The Investigational M72/as01e-4 Mycobacterium Tuberculosis (mtb) Vaccine When Administered Intramuscularly On A 0,1-month Schedule To Adolescents And Adults	Bill & Melinda Gates Medical Research Institute	PT IQVIA RDS Indonesia	Research Center for Care and Control of Infectious Disease (RC3ID) Universitas Padjadjaran	Prof. Dr. dr. Erlina Burhan, Sp.P(K), MSc Prof. dr. Rovina Ruslami, Sp.PD, PhD	Vaksin	M72/AS01E-4	25-11-2024	26-11-2024	Closed	NA
20	A Randomized, Observer Blinded, Active Controlled Phase 3 Study To Evaluate Theimmunogenicity And Safety Of Candidate Recombinant Nonavalent (types6/11/16/18/31/33/45/52/58) Human Papillomavirus (hpv) Vaccine (escherichia Coli) Administered Intramuscularly In Healthy Female Participants Aged 18 To 45 Years"	Beijing Health Guard Biotechnology, Inc	PT Equilab International	RSUP Dr. M.Djamil , Padang	dr. Asrawati, M. Biomed, Sp.A(K)	Vaksin	HPV	17-10-2024	18-10-2024	Closed	NA
21	A Randomized Trial Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1hp) To Weekly Rifapentine & Isoniazid For 3 Months (3hp) In Persons Living With Hiv And In Hiv Negative Household Contacts Of Recently Diagnosed Tuberculosis Patients, The "one To Three" Trial	Yayasan KNCV Indonesia		RSUP Persahabatan	Dr. dr. Erlina Burhan M.Sc, Sp.P(K)	Obat	Rifapentine & Isoniazid	23-07-2024	24-07-2024	Closed	NA
22	A Phase 3, Randomized, Blinded, Active-controlled Study To Evaluate The Immunogenicity And Safety Of Walvax's 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (pcv13-tt) As Compared To Pfizer's 13-valent Pneumococcal Conjugate Vaccine (pcv13) Co-ad	Yuxi Walvax Biotechnologies	PT Prodia DiaCRO Laboratories	Fakultas Kedokteran Universitas Udayana a. Puskesmas I Denpasar Selatan	Dr.dr. I Gusti Ayu Trisna Windiani, SpA(K)	Vaksin	PCV13-TT	27-06-2024	28-06-2024	Closed	Peringatan
23	A Multicenter, Randomized, Double-blinded, Positivec Ontrolled Phase ? Clinical Trial To Evaluate Lot-to-lot Consistency, Immunogenicity And Safety Of Group Acyw135 Meningococcal Conjugate Vaccine (crm197) In Adults Aged 18 To 55 Years	CanSino Biologics Inc..	Tigermed Indonesia	1. RS Universitas Airlangga 2. RS Husada Utama	Dr. dr. Erni Juwita Nelwan, Ph.D, Sp.PD-KPTI, FACP, FINASIM 1. Prof. Dr. dr. Nasronudin, Sp.PD-KPTI, FINASIM 2. dr. Isti Suharjanti, Sp.S(K)	Vaksin	MCV (CRM197)	07-05-2024	08-05-2024	Closed	NA
24	A Phase 3, Randomized, Blinded, Active-controlled Study To Evaluate The Immunogenicity And Safety Of Walvax's 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (pcv13-tt) As Compared To Pfizer's 13-valent Pneumococcal Conjugate Vaccine (pcv13) Co-administered With Epi Vaccines At 2, 4, And 12-15 Months Of Age, To Healthy Infants In Indonesia	Yuxi Walvax Biotechnologies	PT Prodia DiaCRO Laboratories	RSUPN Dr. Cipto Mangunkusumo a. Puskemas Jatinegara	Dr. dr. Nastiti Kaswandari. SpA(K)	Vaksin	PCV13-TT	29-04-2024	30-04-2024	Closed	NA
25	A Randomized, Observer Blinded, Active Controlled Phase 3 Study To Evaluate Theimmunogenicity And Safety Of Candidate Recombinant Nonavalent (types6/11/16/18/31/33/45/52/58) Human Papillomavirus (hpv) Vaccine (escherichia Coli) Administered Intramuscularly In Healthy Female Participants Aged 18 To 45 Years	Beijing Health Guard Biotechnology, Inc	PT Equilab International	RSU Universitas Muhammadiyah Malang	Prof. Dr. dr. Djoni Djunaedi, Sp.PD, KPTI	Vaksin	Vaksin HPV	07-03-2024	08-03-2024	Closed	NA
26	Effectiveness & Safety Of Ovine Enoxaparin Sodium To Originator Enoxaparin In Non-st-segment Elevation Acute Coronary Syndrome (nsteacs) Patients: A Multicenter, Non-randomized, Open-label, Non-inferiority Trial	PT. Bio Farma	Clinical Epidemiology and Biostatistics Unit (CEBU) FKMKM Universitas Gadjah Mada	RS Jantung dan Pembuluh Darah Harapan Kita, Jakarta	Dr. dr. Dafsah Arifa Juzar, Sp.JP(K)	Obat	Enoxaparin	25-01-2024	26-01-2024	Closed	NA
27	Immunobridging Study: Immunogenicity And Safety Of Vaksin Merah Putih â€" Ua Sars-cov-2 (vero Cell Inactivated) Vaccine As Heterologous Booster In Adolescent Subjects Indonesia	1. UNAIR 2. Kemenkes RI 3. PT Biotis		RSUD Dr. Soetomo	Dr. Dominicus Husada, dr., SpA(K)	Vaksin	Vaksin Inavac	07-12-2023	08-12-2023	Closed	NA
28	The Effect Of Incremental Continuous Ambulatory Peritoneal Dialysis On The Preservation Of Residual Kidney Function And Clinical Outcomes: A Randomized Controlled Trial	Prof. dr. Aida Lydia, PhD, Sp.PD-KGH		RSUP Dr. Cipto Mangunkusumo	Prof. dr. Aida Lydia, PhD, Sp.PD-KGH	Obat	Icodextrin	30-11-2023	01-12-2023	Closed	NA
29	Immunogenicity & Safety Of Indovac As A Homologous Booster Dose Against Covid-19 In Adults Aged 18 Years And Above In Indonesia	PT. Bio Farma	PT. Equilab International	Fakultas Kedokteran Universitas Diponegoro a. Puskesmas Mranggen 1, Demak b. Puskesmas Pringapus, Ungaran	dr. Yetty Movieta Nancy, Sp.A (K)	Vaksin	Vaksin Indovac	23-11-2023	24-11-2023	Closed	NA
30	A Parallel Group Treatment, Phase 2/3, Double-blind, Randomized, Placebo-controlled, 3-arm Study To Evaluate The Safety, Tolerability, And Efficacy Of Ad17002 (Ith[ĭsk]) Intranasal Spray In Male And Female Participants Aged 18 To 65 Years With Mild To Moderate Covidâ€™19 A Joint Development By Universitas Gadjah Mada And Advagene Biopharma	Advagene Biopharma Co., Ltd. Taiwan	PT. Equilab International	Rumah Sakit Penyakit Infeksi (RSPI) Prof. Dr. Sulianti Saroso	dr. Adria Rusli, Sp.P	Obat	AD17002	18-09-2023	19-09-2023	Closed	NA
31	High Dose Oral Rifampicin To Improve Survival From Adult Tuberculous Meningitis: A Double-blinded Randomised Controlled Phase Iii Trial (harvest)	Infectious Disease Institute Limited, Uganda		RSUP Dr. Hasan Sadikin Bandung	Prof. Rovina Ruslami, dr., Sp.PD, PhD	Obat	Rifampicin	27-07-2023	28-07-2023	Closed	NA
32	An Open Label, Phase Iii Clinical Trial (immunobridging Study) Of Inavac (vaksin Merah Putih – Ua-sars Cov-2 (vero Cell Inactivated)) In Healthy Population Aged 12 To 17 Years Old	1. UNAIR 2. Kemenkes RI 3. PT. Biotis		RSUD. Dr. Soetomo Surabaya	Dr. Dominicus Husada, dr., SpA(K)	Vaksin	Vaksin Inavac	26-06-2023	27-06-2023	Closed	NA
33	Immunogenicity And Safety Of Indovac As A Heterologous Booster Dose Against Covid-19 In Children 12-17 Years Of Age	PT Bio Farma	PT Equilab International	Departemen Ilmu Kesehatan Anak, FK Universitas Padjadjaran a. Puskesmas Garuda	Dr. dr. Eddy Fadlyana, Sp.A(K), M Kes	Vaksin	Vaksin Indovac	29-05-2023	30-05-2023	Closed	NA

No	Judul Protokol	Sponsor	ORK	Sentra Uji Klinik	Peneliti	Jenis Produk Uji	Nama Produk Uji	Tanggal Mulai Pelaksanaan	Tanggal Selesai Pelaksanaan	Status CAPA	Tindakan Regulator
34	A Randomized, Double-blind, Placebo-controlled Clinical Study To Evaluate The Efficacy, Safety, And Immunogenicity Of Sars-cov-2 Variant (ba.4/5) Mrna Vaccine (abo1020) In Healthy Subjects Aged 18 Years And Older Who Have Completed The Full Vaccination	1. Suzhou Abogen Biosciences Co., Ltd 2. PT Etana Biotechnologies Indonesia	PT. Tigermed Consulting Indonesia	RS Yarsi	dr. Efriadi Ismail, Sp.P	Vaksin	Vaksin mRNA	10-05-2023	12-05-2023	Closed	NA
35	A Randomized, Double-blind, Placebo-controlled Clinical Study To Evaluate The Efficacy, Safety, And Immunogenicity Of Sars-cov-2 Variant (ba.4/5) Mrna Vaccine (abo1020) In Healthy Subjects Aged 18 Years And Older Who Have Completed The Full Vaccination	1. Suzhou Abogen Biosciences Co., Ltd 2. PT Etana Biotechnologies Indonesia	PT. Tigermed Consulting Indonesia	RS Universitas Indonesia	dr. Rania Imaniar, Sp.P	Vaksin	Vaksin mRNA	20-03-2023	21-03-2023	Closed	NA
36	Bevacizumab Compared To Avastin® In Combination With Capecitabine Plus Oxaliplatin (capeox) As First-line Therapy In Metastatic Colorectal Cancer: A Preliminary Open-label Study	PT. Etana Biotechnologies	Clinical Research Supporting Unit (CRSU) FK Universitas Indonesia	RS Kanker Dharmais	dr. Ronald Alexander Hukom, Sp.PD, KHOM, MHSC, FINASIM	Obat	Bevacizumab	20-02-2023	21-02-2023	Closed	NA
37	Open Label Randomised Controlled Trial Of Eferoetin Alfa For Treatment Of Anemia Associated With Chronic Kidney Disease Patients Not On Dialysis (nd-ckd). A Non-inferiority Trial Compared To Methoxy Polyethylene Glycol-epoetin Beta (mircera)	PT. Kalbe Genexine Biologics	PT Pharma Metric Labs	RS Islam Jakarta, Cempaka Putih	dr. Kuspujdi Dwitanto R, SpPD-KGH	Produk Biologi	Eferoetin Alfa	31-01-2023	01-02-2023	Closed	Peringatan
38	Efficacy, Safety And Immunogenicity Of Rotavirus Rv3 Vaccine (bio Farma) In Neonates, Lot To Lot Consistency And Antigen Interference With Co-administered Epi Vaccines (phase Iii)	PT. Bio Farma	IQVIA RDS Indonesia	Pediatric Research Center Universitas Sebelas Maret (PRC UNS)	dr. Hary Wahyu N, M.Kes., Sp.A(K)	Vaksin	Vaksin Rotavirus	25-01-2023	26-01-2023	Closed	NA
39	A Phase Iii, Observer-blind, Randomized, Controlled Study Of The Safety And Immunogenicity Of Sars-cov2 Protein Subunit Recombinant Vaccine In Healthy Children Aged 12-17 Years In Indonesia	PT. Bio Farma	PT. Equilab International	Pediatric Research Office (PKKA-PRO) Universitas Gadjah Mada a. RS Universitas Mataram, Nusa Tenggara Barat	dr. Cahya Dewi Satria, M.Kes., Sp.A(K). a. dr. Putu Aditya Wiguna M.Sc Sp.A	Vaksin	Vaksin IndoVac	13-12-2022	14-12-2022	Closed	NA
40	A Phase Iii, Observer-blind, Randomized, Controlled Study Of The Safety And Immunogenicity Of Sars-cov-2 Protein Subunit Recombinant Vaccine In Healthy Children Aged 12-17 Years In Indonesia	PT. Bio Farma	PT. Equilab International	Pediatric Research Office (PKKA-PRO) Universitas Gadjah Mada a. RSUD Dr. H. Abdoel Moeloek, Lampung	dr. Cahya Dewi Satria, M.Kes., Sp.A(K). a. dr. Prambudi Rukmono, Sp.A(K)	Vaksin	Vaksin IndoVac	01-12-2022	02-12-2022	Closed	NA
41	A Phase 2, Randomized, Double-blinded, Placebo-controlled, Parallel Group, Single Administration Study To Evaluate The Safety And Efficacy Of Gx-i7 In Elderly Patients With Severe Acute Respiratory Syndrome Coronavirus (sars-cov-2) Infection	1. Genexine, Inc. Korea 2. PT Kalbe Genexine Biologics	PT. Pharma Metric Labs	1. RS Mitra Keluarga Bintaro 2. RS Ukrida	1. Dr. Okki Ramadian, SpPD 2. dr. Chrispian Oktafbipian Mamudi, Sp.PD-KP	Produk Biologi	GX-I7	23-11-2022	24-11-2022	Closed	
42	A Global, Multi-center, Randomized, Double-blind, Placebo-controlled, Phase Iii Clinical Study To Evaluate The Protective Efficacy, Safety And Immunogenicity Of Sars-cov-2 Messenger Ribonucleic Acid (mna) Vaccine In Population Ased 18 Years And Older	1. Suzhou Abogen Biosciences Co., Ltd. China 2. PT. Etana Biotechnologies Indonesia	PT. Tigermed Consulting Indonesia	Rumah Sakit Umum Pusat Persahabatan, Jakarta a. Puskesmas Mauk, Kabupaten Tangerang	Dr. dr. Erlina Burhan, MSc, SpP(K)	Vaksin	Vaksin mRNA	16-11-2022	18-11-2022	Closed	NA
43	Observer-blind, Randomized, Controlled Study Of Immunogenicity And Safety Of Sars-cov-2 Protein Subunit Recombinant Vaccine (bio Farma) As A Booster Dose Against Covid-19 In Adults 18 Years Of Age And Older	PT. Bio Farma	PT Equilab International	RSUP Prof. I.G.N.G Ngoerah-FK Universitas Udayana	Dr.dr.I Gusti Ayu Trisna Windiani, Sp.A(K)	Vaksin	Indovac	27-10-2022	28-10-2022	Closed	NA
44	A Randomized, Double-blind, And Placebo-controlled Phase 1 Clinical Study To Evaluate The Safety, Tolerability, And Immunogenicity Of Sars-cov-2 Variant Mrna Vaccines (abo1009-dp And Abo-cov.617.2) In Indonesian Subjects Aged 18 Years And Older Who Have Not Received Sars-cov-2 Vaccines	1. Suzhou Abogen Biosciences Co., Ltd. 2. PT Etana Biotechnologies Indonesia	PT. Tigermed Consulting Indonesia	1. RSUP Persahabatan 2. RSUPN Dr. Cipto Mangunkusumo	Dr. dr. Erlina Burhan, MSc, Sp.P(K) 1. Dr. dr. Fathiyah Isbaniah, Sp. P(K), MPd, Ked 2. Dr. dr. Sukamto Koesnoe, Sp.PD-KAI	Vaksin	SARS-CoV-2 Variant mRNA Vaccines (ABO1009-DP and ABO-CoV.617.2)	19-10-2022	21-10-2022	Closed	NA
45	Observer-blind, Randomized, Controlled Study Of Immunogenicity And Safety Of Sars-cov-2 Protein Subunit Recombinant Vaccine (bio Farma) As A Booster Dose Against Covid-19 In Adults 18 Years Of Age And Older	PT. Bio Farma	PT. Equilab International	Departemen Ilmu Kesehatan Anak, Fakultas Kedokteran Universitas Padjadjaran	Prof. Dr. dr. Kusnandi Rusmil, SpA(K), MM	Vaksin	Vaksin IndoVac	13-10-2022	14-10-2022	Closed	NA
46	2r2: Higher Dose Rifampin For 2 Months Vs Standard Dose Rifampin For Latent Tb:a 3-arm Randomized Trial	Mcgill International TB Centre, Canada		FK Universitas Padjadjaran Bandung	Prof. Rovina Ruslami, dr., Sp.PD, PhD	Obat	Rifampicin	29-09-2022	30-09-2022	Closed	NA
47	A Multicenter, Randomized, Double Blind, Controlled, Phase Iii Clinical Trial (immunobridging Study) Of Vaksin Merah Putih – Ua Sars-cov-2 (vero Cell Inactivated) In Healthy Population Aged 18 Years And Above	1. BKPK Kemenkes RI 2. PT Biotis 3. Universitas Airlangga		RSUD Dr. Soetomo, Surabaya a. RS Paru Jember b. RSUD. Dr. Soebandi, Jember	Dr. Dominic Husada, dr., Sp.A(K) a. dr. Sigit Kusuma Jati, MM b. dr. Retna Dwi Puspitarini, Sp.P	Vaksin	Inavac	22-09-2022	23-09-2022	Closed	Peringatan
48	Safety, Tolerability, Immunogenicity And Protective Efficacy Against Naturally-transmitted Malaria In Eastern Indonesia Of Two Plasmodium Falciparum Sporozoite Vaccines, Sanaria® Pfspz Vaccine And Sanaria® Pfspz-cvac: A Randomized, Double-blind, Placebo-controlled Phase 2 Trial In Healthy Indonesian Adults	Sanaria Inc, USA	Eijkman Oxford Clinical Research Unit (EOCRU)	Divisi Penyakit Infeksi dan Tropis, Departemen Penyakit Dalam, Fakultas Kedokteran Universitas Indonesia Jakarta a. Markas Batalyon Infanteri 132 Bangkinang, Riau	DR. Dr. Erni J. Nelwan, SpPD, KP, PhD	Vaksin	Sanaria® PfSPZ Vaccine, Sanaria® PfSPZ-CVAc	01-09-2022	02-09-2022	Closed	NA

No	Judul Protokol	Sponsor	ORK	Sentra Uji Klinik	Peneliti	Jenis Produk Uji	Nama Produk Uji	Tanggal Mulai Pelaksanaan	Tanggal Selesai Pelaksanaan	Status CAPA	Tindakan Regulator
49	Immunogenicity & Safety Of Sars-cov-2 Protein Subunit Recombinant Vaccine (bio Farma) Adjuvanted With Alum+cpg 1018 Compared To Registered Covid-19 Vaccine (covovax â€” Protein Subunit Vaccine) In Healthy Populations Aged 18 Years And Above In Indonesia (phase Iii)	PT. Bio Farma	PT. Equilib International	Fakultas Kedokteran Universitas Andalas Padang a. RS Universitas Andalas b. RSUD Padang Pariaman	dr. Asrawati, M.Biomed, SpA(K)	Vaksin	Vaksin IndoVac	18-07-2022	19-07-2022	Closed	NA
50	A Phase Iiib/iv Randomized Open Label Trial To Compare Dolutegravir With Pharmac-enhanced Darunavir Versus Dolutegravir With Predetermined Nucleosides Versus Recommended Standard Of Care Antiretroviral Regimens In Patients With Hiv-1 Infection Who Have Failed Recommended First Line Therapy	University of New South Wales, Australia	INA RESPOND (Badan Kebijakan Pengembangan Kesehatan)	RSUPN Dr. Cipto Mangunkusumo	Dr. dr. Evy Yuniastuti, Sp.PD-KAI FINASIM	Obat	Dolutegravir,Darunavir	14-07-2022	15-07-2022	Closed	NA
51	Studi Klinis Fase Iii, Acak, Tersamar Ganda, Terkontrol Placebo Untuk Mengevaluasi Efikasi Dan Keamanan Proxalutamide (gt0918) Pada Pasien Rawat Inap Covid-19	PT. Etana Biotechnologies Indonesia		RSUP Persahabatan	dr. Triya Damayanti,SpP(K), PhD	Obat	Proxalutamide	29-06-2022	30-06-2022	Closed	NA
52	Immunogenicity And Safety Study Of Half Dose Of Moderna Covid-19 Vaccine Booster Heterologous In Adult Subjects In Indonesia	Badan Kebijakan Pembangunan Kesehatan, Kementerian Kesehatan Republik Indonesia		Fakultas Kedokteran Universitas Indonesia - RSCM a. Puskesmas Cempaka Putih	dr. Nina Dwi Putri, Sp.A(K)	Vaksin	Vaksin Moderna	18-05-2022	19-05-2022	Closed	NA
53	Safety And Immunogenicity Of Unair Inactivated Covid-19 Vaccine In Healthy Population Aged 18 Years And Above (phase I/ii)	1. BKPK Kemenkes RI 2. PT Biotis 3. Unair		RSUD Dr. Soetomo, Surabaya	Dr. Dominic Husada, dr., Sp.A(K)	Vaksin	Inavac	24-03-2022	25-03-2022	Closed	NA
54	A Phase Ii Non-randomized Open Labelled Clinical Trial To Evaluate The Safety & Immunogenicity Of Sars-cov-2 Vaccine (vero Cell) Inactivated As A Booster Dose	PT Kimia Farma		Laboratorium Klinik Kimia Farma Radio Dalam, Jakarta	dr Andi Wiradharma, SpPK	Vaksin	Vaksin SARS-COV-2 (Vero Cell) Sinopharm	14-03-2022	15-03-2022	Closed	NA
55	Safety And Immunogenicity Of Unair Inactivated Covid-19 Vaccine In Healthy Population Aged 18 Years And Above (phase I/ii)	1. BKPK 2. UNAIR 3. PT Biotis		RSUD Dr. Soetomo, Surabaya	Dr. Dominic Husada, dr., Sp.A(K)	Vaksin	Vaksin Inavac	02-02-2022	03-02-2022	Closed	NA
56	Global, Multi-center, Randomized, Double-blind, Placebo-controlled, Phase Iii Clinical Study To Evaluate The Protective Efficacy, Safety, And Immunogenicity Of Recombinant Sars-cov-2 Fusion Protein Vaccine (v-01) In Adults Aged 18 Years And Older	Livzon	PT. Equilib International	Fakultas Kedokteran Universitas Islam Negeri Syarif Hidayatullah a. KP KM Renijaya, Tangerang	Dr. Hari Hendarto, PhD, SpPD-KEMD, FINASIM	Vaksin	Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)	20-01-2022	26-01-2022	Closed	NA
57	Immunogenicity And Safety Study Of Half And Full Dose Of Heterologous And Homologous Covid-19 Vaccine Booster In Adult Subjects In Indonesia (bcov-21)	Badan Penelitian dan Pengembangan Kesehatan, Kementerian Kesehatan Republik Indonesia (Balitbangkes, Kemenkes RI)		RSUP Dr. Hasan Sadikin Bandung a. Klinik Kesehatan Unpad b. Puskesmas Ciumbuleuit	Dr. Djatnika Setiabudi, dr., SpA(K)	Vaksin	Vaksin AstraZeneca, Pfizer, Sinovac	23-12-2021	24-12-2021	Closed	NA
58	A Phase I/ii, Placebo-controlled, Randomized, Double-blind, Dose-finding Study To Evaluate The Safety, Tolerability, And Immunogenicity Of Adimrsc-2f Vaccine In Healthy Adults	Adimmune Corporation, Taiwan	PT. IQVIA RDS Indonesia	Rumah Sakit Akademik Universitas Gadjah Mada, Yogyakarta	Supriyati, Dr., S.Sos., M.Kes	Vaksin	Vaksin AdimrSc-2f	13-12-2021	14-12-2021	Closed	NA
59	A Global Multicenter, Randomized, Double-blind, Placebo-controlled, Phase Iii Clinical Trial To Evaluate The Efficacy, Safety, And Immunogenicity Of Recombinant Covid-19 Vaccine (sf9 Cells), For The Prevention Of Covid-19 In Adults Aged 18 Years And Older	1. WestVac Biopharma Co., Ltd, 2. West China Hospital of Sichuan University	PT. Equilib International dan PT. Tigermed Consulting Indonesia	RSUP Persahabatan a. Puskesmas Ciketingudik, Bekasi	dr. Sita Andarini, Sp.P(K), Ph.D a. dr. Elisabeth Intan Budi Pratiwi	Vaksin	Vaksin Sf9	08-12-2021	10-12-2021	Closed	NA
60	A Global, Multi-center, Randomized, Double-blind, Placebo-controlled, Phase Iii Clinical Study To Evaluate The Protective Efficacy, Safety And Immunogenicity Of Sars-cov-2 Messenger Ribonucleic Acid (mna) Vaccine In Population Aged 18 Years And Older	1. Yuxi Walvax Biotechnology Co., Ltd., 2. Walvax Biotechnology Co., Ltd., 3. Suzhou Abogen Biosciences Co., Ltd., 4. PT. Etana Biotechnologies Indonesia	PT. Tigermed Consulting Indonesia	RSUP Persahabatan a. Puskesmas Kecamatan Pulogadung b. Puskesmas Kecamatan Kalideres	dr. Erlina Burhan, MSc, Sp.P(K) a. dr. Titta Gusni Salim b. dr. Linda Lidya, M. Epid	Vaksin	Vaksin ARCoV	03-12-2021	07-12-2021	Closed	NA
61	A Phase I, Observer-blind, Randomized, Controlled Study Of The Safety And Immunogenicity Of Sars-cov-2 Protein Subunit Recombinant Vaccine In Healthy Populations Aged 18 Years And Above In Indonesia	1. Badan Penelitian dan Pengembangan Kesehatan, Kementerian Kesehatan Republik Indonesia 2. PT Bio Farma		Departemen Ilmu Kesehatan Anak, Fakultas Kedokteran Universitas Indonesia a. Puskesmas Pancoran Mas, Depok	Prof. Dr. dr. Rini Sekartini, SpA (K)	Vaksin	SARS-CoV-2 Protein Subunit Recombinant Vaccine	26-11-2021	27-11-2021	Closed	NA
62	Randomised Evaluation Of Covid-19 Therapy (recovery)	University of Oxford	Eijkman-Oxford Clinical Research Unit	RS Metropolitan Medical Center (MMC), Jakarta	dr. Sandhi Prabowo, Sp.An-KIC	Obat	Colchicine, Dexamethasone, Empaglifozine	08-11-2021	10-11-2021	Closed	NA
63	Uji Klinik Acak Tersamar Ganda Untuk Membandingkan Efikasi Pemberian Remdesivir 5 Dan 10 Hari Pada Pasien Covid-19 Rawat Inap Derajat Sedang Dan Berat (covid-remisi)	Badan Penelitian dan Pengembangan Kesehatan, Kementerian Kesehatan Republik Indonesia (Balitbangkes, Kemenkes RI)		RSUP Persahabatan Jakarta	dr. Fathiyah Isbaniah, Sp.P(K)	Obat	Remdesivir	11-10-2021	15-10-2021	Closed	NA
64	Efficacy And Safety Of Normoxic Allogenic Umbilical Cord Mesenchymal Stem Cells Administered As Adjunctive Treatment To Standard Treatment In Severe Patients With Covid-19	Badan Riset dan Inovasi Nasional (BRIN), Bifarma Adiluhung	PT Pharma Metric Labs	RSUD Dr. Moewardi, Surakarta	Dr. dr. Arief Nurudhin, Sp.PD, K-R, FINASIM	Produk Biologi	UCMSC	20-09-2021	24-09-2021	Closed	NA
65	Uji Klinik Fase Ii-iii, Acak, Tersamar Ganda Dengan Kontrol Placebo Untuk Menilai Keamanan Dan Efikasi Pemberian Oral Ivermectin Pada Pasien Covid-19 Derajat Ringan-sedang-berat	Badan Penelitian dan Pengembangan Kesehatan, Kemenkes RI		RSUD dr Soedarso, Pontianak	DR.dr.Pinda Hutajulu,SPOG,(K)-FER	Obat	Ivermectin	13-09-2021	17-09-2021	Closed	NA
66	Uji Klinik Pemberian Plasma Konvalesen Sebagai Terapi Tambahan Covid-19 (plasenter)	Badan Penelitian dan Pengembangan Kesehatan, Kementerian Kesehatan Republik Indonesia		RSAL dr. Ramelan Surabaya	Kol. Laut (K) dr. Frans O.H.P,SpOG(K)	Produk Biologi	Plasma Konvalesen	12-08-2021	20-08-2021	Closed	NA
67	Uji Klinik Pemberian Plasma Konvalesen Sebagai Terapi Tambahan Covid-19 (plasenter)	Badan Penelitian dan Pengembangan Kesehatan, Kementerian Kesehatan Republik Indonesia		RSD Gunung Jati Cirebon	dr. Agung Hujjatulislam, Sp.An. KIC	Produk Biologi	Plasma Konvalesen	12-08-2021	20-08-2021	Closed	NA

No	Judul Protokol	Sponsor	ORK	Sentra Uji Klinik	Peneliti	Jenis Produk Uji	Nama Produk Uji	Tanggal Mulai Pelaksanaan	Tanggal Selesai Pelaksanaan	Status CAPA	Tindakan Regulator
68	A Phase Iii Randomized, Double-blind, Placebo-controlled Clinical Trial In 18 Years Of Age And Above To Determine The Safety And Efficacy Of Zf2001, A Recombinant Novel Coronavirus Vaccine (cho Cell) For Prevention Of Covid-19	Anhui Zhifei Longcom Biopharmaceutical Co., Ltd., China	PT. Prodia DiaCRO Laboratories	Departemen Ilmu Kesehatan Anak FK UI-RSUPN Dr. Cipto Mangunkusumo	Prof. Dr. dr. Hindra Irawan, Sp.A(K),M.Trop.Paed	Vaksin	Zifivax	17-06-2021	18-06-2021	Closed	NA
69	Efficacy And Safety Of Convalescent Plasma Transfusion Administered As Adjunctive Treatment To Standard Treatment In Moderate, Severe, And/or Critically Ill Patients With Covid-19	Kementerian Riset dan Teknologi – Badan Riset dan Inovasi Nasional		RSUP Dr. Sardjito Yogyakarta	Dr. Johan Kurnianda, SpPD-KHOM	Produk Biologi	Plasma Konvalesen	15-06-2021	16-06-2021	Closed	NA
70	A Phase Iii Randomized, Double-blind, Placebo-controlled Clinical Trial In 18 Years Of Age And Above To Determine The Safety And Efficacy Of Zf2001, A Recombinant Novel Coronavirus Vaccine (cho Cell) For Prevention Of Covid-19	Anhui Zhifei Longcom Biopharmaceutical Co., Ltd., China	PT. Prodia DiaCRO Laboratories	Departemen Ilmu Kesehatan Anak FK UNPAD-RSHS, Bandung	dr. Rodman Tarigan, Sp.A (K), M.Kes	Vaksin	Vaksin Zifivax	25-03-2021	26-03-2021	Closed	NA
71	Uji Klinis Adaptif Fase I Sel Dendritik Autolog Yang Sebelumnya Diinkubasi Dengan Spike Protein Severe Acute Respiratory Syndrome Coronavirus-2 (sars-cov-2) Pada Subjek Yang Tidak Terinfeksi Covid-19 Dan Tidak Terdapat Antibodi Anti Sars-cov-2	Balitbangkes, Kemenkes RI		RSUP Dr. Kariadi Semarang	Dr. dr. Muchlis Achsan Udji, SpPD-KPTI, FINASIM	Produk Biologi	Sel Dendritik Autolog	12-03-2021	13-03-2021	Closed	Peringatan
72	Fase Iii, Acak-terbuka, Uji Klinik Efikasi Dan Keamanan Favipiravir Pada Pasien Covid-19 Di Indonesia	Badan Penelitian dan Pengembangan Kesehatan, Kementerian Kesehatan RI		1. RSJ Prof.Dr.Soerojo, Magelang a. 2. RS TTK II dr. Soedjono, Magelang a. 3. RS Merah Putih, Magelang a.	Dr. dr. Armydy Ronny Hasugian, M.Biomed 1. dr. Harli Amir Mahmudji, Sp.PD, KEMD 2. dr. Dwi Hartanto, Sp.P, FIRS 3. dr. Ratna Sulistyani, Sp.PD	Obat	Favipiravir	17-12-2020	18-12-2020	Closed	NA
73	Uji Klinis Adaptif Fase I Sel Dendritik Autolog Yang Sebelumnya Diinkubasi Dengan Spike Protein Severe Acute Respiratory Syndrome Coronavirus-2 (Sars-cov-2) Pada Subjek Yang Tidak Terinfeksi Covid-19 Dan Tidak Terdapat Antibodi Anti Sars-cov-2	PT. AIVITA Biomedika Indonesia		RSUP Dr. Kariadi Semarang	Dr. dr. Muchlis Achsan Udji, SpPD-KPTI, FINASIM	Produk Biologi	Sel dendritik	14-12-2020	15-12-2020	Closed	
74	Penggunaan Sel Punca Mesenkimal Asal Tali Pusat Sebagai Terapi Pasien Dengan Covid-19 Pneumonia Derajat Kritis	PT Kimia Farma (Persero)		RSUP Persahabatan	Prof. Dr. dr. Ismail Hadisoebroto Dilogo, Sp.OT(K)	Produk Biologi	Sel punca mesenkimal	12-10-2020	27-10-2020	Closed	
75	Penggunaan Sel Punca Mesenkimal Asal Tali Pusat Sebagai Terapi Pasien Dengan Covid-19 Pneumonia Derajat Kritis	PT Kimia Farma (Persero)		RSUPN Dr. Cipto Mangunkusumo-Fakultas Kedokteran Universitas Indonesia	Prof. Dr. dr. Ismail Hadisoebroto Dilogo, Sp.OT(K)	Produk Biologi	Sel punca mesenkimal	22-09-2020	02-10-2020		
76	Penilaian Efikasi Dan Keamanan Injeksi Bdb-001 Untuk Pengobatan Covid-19 Berat Dan Progresif: Suatu Uji Klinik Fase Ii, Multisenter, Berpembanding, Paralel, Acak Dan Terbuka	Staidson (Beijing) Biopharmaceutical Co., Ltd	PT Etana Biotechnologies Indonesia	1. RSUD Pasar Minggu 2. RSUP Persahabatan	1. Dr. dr. Erlina Burhan, MSc, Sp.P(K) 2. 3.	Obat	BDB-001	20-09-2020	25-09-2020	Closed	
77	A Phase Iii, Observer-blind, Randomized, Placebo Controlled Study Of The Efficacy, Safety And Immunogenicity Of Sars-cov-2 Inactivated Vaccine In Healthy Adults Aged 18-59 Years In Indonesia	PT Bio Farma		Bagian Ilmu Kesehatan Anak RS Hasan Sadikin Bandung a. Fakultas Kedokteran UNPAD b. Balai Kesehatan UNPAD c. Puskesmas Garuda d. Puskesmas Ciumbuleuit e. Puskesmas Dago f. Puskesmas Sukapakir	Prof. Dr. Kusnandi Rusmil, dr.,Sp.A(K),MM	Vaksin	Vaksin COVID-19	08-09-2020	09-09-2020	Closed	NA
78	An International Randomised Trial Of Additional Treatments For Covid-19 In Hospitalised Patients Who Are All Receiving The Local Standard Of Care (solidarity Trial)	World Health Organization (WHO)		1. RSPI Suliarti Saroso 2. RS YARSI, Jakarta	1. Dr. dr. Indra Kusuma,M.Biomed 2. 3.	Obat		07-09-2020	15-09-2020	Closed	
79	Studi Acak,berpembanding,terbuka Untuk Mengetahui Efektivitas Dan Keamanan Favipiravir Sebagai Terapi Tambahan Terhadap Pengobatan Standar Pada Penderita Covid-19	Kementerian BUMN melalui PT. Pertamina Bina Medika IHC	Indonesia Healthcare Corporation	RSUPN Cipto Mangunkusumo,Jakarta		Obat	Favipiravir	19-08-2020	25-08-2020		
80	Uji Klinik Fase Iii, Multisenter, Acak Terkontrol, Tersamar Ganda Membandingkan Efikasi Dan Keamanan Kombinasi Baru Lopinavir/ritonavir Azytromycin, Lopinavir/ritonavir Doxycycline, Serta Hydroxychloroquine Azytromycin Dengan Obat Standar Pada Pasien Covid-19 Yang Dirawat Di Rumah Sakit Dengan Derajat Ringan, Sedang, Dan Berat Yang Tidak Menggunakan Ventilator	Badan Intelijen Negara (BIN)		RS Dustira Bandung	Dr. Purwati, dr., Sp.PD.,FINASIM.	Obat	Kombinasi Lopinavir/Ritonavir	27-07-2020	28-07-2020	Closed	
81	Pharmacodynamic Equivalence Of Ovine Enoxaparin To Porcine Enoxaparin (lovenox®) In Healthy Volunteers	PT. Metiska Farma		PT. Pharma Metric Labs, Jakarta	Prof. Arini Setiawati, PhD	Obat	Enoxaparin	10-02-2020	11-02-2020	Closed	
82	Safety And Preliminary Of Immunogenicity Following Recombinant Hepatitis B (bio Farma) Vaccine In Adults & Children (phase I)	PT Bio Farma		Fakultas Kedokteran Universitas Padjadjaran, RSUP Dr. Hasan Sadikin, Bandung	1. Prof. Dr. Kusnandi Rusmil, dr., Sp.A(K), MM 2.	Vaksin	Vaksin Hepatitis B	10-02-2020	11-02-2020	Closed	NA
83	Non-interventional Study On Effectiveness And Safety Of Fixed Dose Combination Of Netupitant And Palonosetron (nepa) In Chemotherapy Induced Nausea And Vomiting (cinv) Patients Receiving Moderately (mec) Or Highly Emetogenic Chemotherapy (hec)	Mundipharma Laboratories GmbH	PT Prodia Diacro Laboratories	1. RS Medistra Jakarta 2. RS Kanker Dharmais	Dr.dr.Hilman Tadjoedin, SpPD-KHOM	Obat	Netupitant	16-12-2019	17-12-2019	Closed	NA

No	Judul Protokol	Sponsor	ORK	Sentra Uji Klinik	Peneliti	Jenis Produk Uji	Nama Produk Uji	Tanggal Mulai Pelaksanaan	Tanggal Selesai Pelaksanaan	Status CAPA	Tindakan Regulator
84	Protectivity And Safety Following Recombinant Hepatitis B Vaccine With Different Source Of Hepatitis B Bulk Compared To Hepatitis B (bio Farma) Vaccine In Indonesian Population	PT Bio Farma		FK Universitas Diponegoro - RS Nasional Diponegoro Semarang a. SD Negeri Bulusan b. SMP Negeri 17 Semarang	Dr. Yetty Movieta Nancy Sp.AK	Vaksin	Hepatitis B Vaccine	28-10-2019	30-10-2019	Closed	NA
85	Studi Farmakokinetik Inapant Susuk Satu Batang 150 Mg Yang Diproduksi Oleh Pt. Catur Dakwah Crane Farmasi, Indonesia Dibandingkan Dengan Sino-implant (ii) Susuk Dua Batang 2 X 75 Mg (150 Mg) Yang Diproduksi Oleh Shanghai Dahua Pharmaceuticals Co.ltd., Cina	PT Catur Dakwah Crane Farmasi		RS Ibu Anak Kendangsari	Dr. Damayanti Rusli Sjarif, PhD, SpA(K)	Obat	Inapant	08-10-2019	09-10-2019	Closed	NA
86	A Randomized Double Blind Placebo Controlled Trial Of Adjunctive Dexamethasone For The Treatment Of Hiv-infected Adults With Tuberculous Meningitis	University of Oxford	Eijkman Oxford Clinical Researh Unit (EOCRU)	FK Universitas Indonesia – RSUP Persahabatan	dr. Erlina Burhan, Sp.P	Obat	Dexamethasone	22-07-2019	23-07-2019	Closed	NA
87	Safety And Efficacy Of Early-start Deferiprone Treatment In Infants And Young Children Newly Diagnosed With Transfusion-dependent Beta Thalassemia	ApoPharma Inc, Canada	PT. IQVIA	Departemen Ilmu Kesehatan Anak, FK Universitas Indonesia – RSUPN Dr. Cipto Mangunkusumo	Dr.dr. Pustika Amalia Wahidiyat SpA(K)	Obat	Deferiprone	16-07-2019	17-07-2019	Closed	NA
88	Two-month Regimens Using Novel Combinations To Augment Treatment Effectiveness For Drug-sensitive Tuberculosis	University College London	PT. INC Research Indonesia	FK Universitas Hasanudin – RS. Wahidin Sudirohusodo Makassar	Dr.dr Irawaty Djaharuddin, Sp.P(K)	Obat	TRUNCATE-TB	09-07-2019	10-07-2019	Closed	NA
89	Two-month Regimens Using Novel Combinations To Augment Treatment Effectiveness For Drug-sensitive Tuberculosis	University College London	PT. INC Research Indonesia	FK Universitas Brawijaya – RSUD dr. Saiful Anwar	Dr.Yani Jane R. Sugiri, Sp.P(K)	Obat	TRUNCATE-TB	29-04-2019	30-04-2019	Closed	NA
90	Safety And Immunogenicity Of Vi-dt Typhoid Conjugate Vaccine (bio Farma) In Indonesian Adults, Adolescents, Children And Infants (phase II)	PT. Bio Farma (Persero)	PT. Prodia Diacro Laboratories	Departemen Ilmu Kesehatan Anak, Fakultas Kedokteran Universitas Indonesia – RSCM a. Puskesmas Jatinegara b. Puskesmas Senen	dr. Bernie Endyarni Medise, SpA(K), MPH	Vaksin	Vi-DT Typhoid Conjugate Vaccine	13-03-2019	14-03-2019	Closed	NA